Alembic Pharmaceuticals has received an Establishment
Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at its Injectable Facility (F-3) at Karkhadi from 18 August, 2022 to 30 August, 2022. This was a pre-approval inspection for ANDAs filed with the USFDA. The Company has already started receiving ANDA approvals manufactured at this facility.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
